Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says
This article was originally published in The Tan Sheet
Executive Summary
Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18You may also be interested in...
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: